Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
The Japanese drug discovery firm PeptiDream has added Bayer to the list of major drug firms with which it collaborates. Its agreement with Bayer involves identifying macrocyclic and constrained peptides from PeptiDream’s peptide library for use against targets selected by Bayer. Promising compounds will be optimized into therapeutic peptides or small-molecule drugs. PeptiDream will receive an up-front fee as part of the agreement and could receive as much as $1.1 billion in milestone payments. The Japanese firm has similar agreements with drugmakers including Merck & Co., Janssen, and Bristol-Myers Squibb.
This article has been sent to the following recipient: